Key result
STAGED trial compares early versus delayed staged complete revascularization for major cardiovascular events in multivessel STEMI.
Why the study?
Complete revascularization reduces adverse cardiovascular events over culprit-only revascularization in STEMI with multivessel disease, but the optimal timing of staged complete revascularization after primary PCI remains unclear.
Does early-staged PCI compared to delayed-staged PCI improve MACE in acute STEMI patients with multivessel disease?
RCT (n=1,586)
Yes
Does early-staged PCI compared to delayed-staged PCI improve MACE in acute STEMI patients with multivessel disease?
The STAGED trial will evaluate the optimal timing (early vs delayed) of staged complete revascularization in STEMI patients with multivessel disease.
Answers are grounded in this paper and cite their sources.
Provides first RCT of staged revascularization timing in multivessel STEMI; will guide whether early or delayed PCI optimizes outcomes.
BACKGROUND Complete revascularization (CR) has been shown to reduce the risk of adverse cardiovascular events compared with culprit-only revascularization (COR) in acute ST-segment elevation myocardial infarction (STEMI) patients with multi-vessel disease (MVD). However, the optimal timing of staged complete revascularization (SCR) after primary percutaneous coronary intervention (PCI) remains unclear. TRIAL DESIGN The STAGED trial is an investigator-initiated, multicenter, randomized study involving 37 sites, aiming to include 1,586 acute STEMI patients with MVD undergoing successful primary PCI of the culprit lesion followed by SCR. Eligible patients will be assigned to two groups based on the timing of SCR: early-staged PCI and delayed-staged PCI. The primary endpoint is major adverse cardiac event (MACE), including cardiovascular death, myocardial infarction, or ischemia-driven revascularization for both culprit and non-culprit vessels at 12 months since the randomization. The secondary endpoint is individual components of primary endpoint, all-cause death, heart failure-related rehospitalization, stroke, contrast-induced nephropathy, and radiation exposure dose . Follow-up will be conducted through clinic visits or telephone interviews at 1, 3, and 12 months after the index procedure. CONCLUSION The STAGED trial is the first randomized controlled study specifically designed to evaluate the clinical efficacy and safety of different timing strategies for SCR in acute STEMI patients with MVD. TRIAL REGISTRATION clinicaltrials.gov, NCT04918030.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted an RCT in Acute ST-segment elevation myocardial infarction (STEMI) with multi-vessel disease (MVD) (n=1,586). Early-staged PCI vs. Delayed-staged PCI was evaluated on Major adverse cardiac event (MACE), including cardiovascular death, myocardial infarction, or ischemia-driven revascularization for both culprit and non-culprit vessels at 12 months. The STAGED trial will randomize 1,586 acute STEMI patients with multivessel disease to early versus delayed staged complete revascularization to evaluate 12-month major adverse cardiac events.
Synapse has enriched 10 related papers. Consider them for comparative context: